3V Medical Research Group

3V Medical Research Group is a private, pre-revenue biotech focused on drug delivery for high-prevalence conditions. Its pipeline includes two pre-clinical assets targeting major viral infections and significant pain indications. The company emphasizes a development strategy built on safety, simple active ingredients, and established delivery methods, supported by a portfolio of pending and approved patents and trademarks. Its success hinges on advancing these candidates through clinical validation and into markets with substantial unmet needs.

A drug delivery platform focused on reformulating and repositioning simple, well-understood molecules using established delivery mechanisms (e.g., suspension for respiratory delivery, cream for topical delivery) to create targeted therapies for new indications.

For Luxsol™, competitors range from large pharma antivirals (e.g., Pfizer's Paxlovid) and vaccines to numerous biotech candidates. For Ostrolux™, competition includes over-the-counter topical analgesics, prescription NSAIDs, opioids, and specialized dermatology products. 3V's differentiation must come from superior efficacy, safety, or delivery convenience.